MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Xtant Medical Holdings Gross Profit 2011-2025 | XTNT
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Xtant Medical Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68.2 M | 55.5 M | 32.1 M | 32.5 M | 34.4 M | 42.5 M | 43.5 M | 50.1 M | 62.3 M | 39.1 M | 22.3 M | 18.9 M | 22.6 M | 21 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 68.2 M | 18.9 M | 38.9 M |
Quarterly Gross Profit Xtant Medical Holdings
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 M | 24.3 M | - | 16.3 M | 18.6 M | 17.3 M | - | 15.3 M | 12.5 M | 10.5 M | - | 7.9 M | 8.37 M | 7.56 M | - | 7.19 M | 9.52 M | 8.09 M | - | 9.25 M | 6.55 M | 9.61 M | - | 10.4 M | 9.91 M | 10.8 M | - | 11.5 M | 12.5 M | 12.2 M | - | 11.4 M | 13.5 M | 14.9 M | - | 16 M | 14.7 M | 14.1 M | - | 11.7 M | 6.52 M | 6.03 M | - | 5.44 M | 5.59 M | 5.5 M | - | 4.61 M | 4.69 M | 5.5 M | - | 6.28 M | 5.88 M | 5.91 M | - | 6.22 M | 5.77 M | 5.01 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24.3 M | 4.61 M | 10.3 M |
Gross Profit of other stocks in the Medical devices industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
67.9 M | - | - | $ 1.77 B |  USA |
 |
Abiomed
ABMD
|
690 M | - | - | $ 17.2 B | USA |
 |
Acutus Medical
AFIB
|
-3.14 M | - | -26.83 % | $ 2.62 M | USA |
 |
Apyx Medical Corporation
APYX
|
33.8 M | $ 3.79 | -1.81 % | $ 131 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
584 K | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
342 M | $ 304.01 | -1.33 % | $ 8.58 B | USA |
 |
Apollo Endosurgery
APEN
|
42.4 M | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
229 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
1.65 B | $ 45.24 | 0.24 % | $ 6.74 K | USA |
 |
Allied Healthcare Products
AHPI
|
443 K | - | 3.58 % | $ 2.21 M | USA |
 |
Abbott Laboratories
ABT
|
18.7 B | $ 128.52 | 2.43 % | $ 224 B | USA |
 |
Boston Scientific Corporation
BSX
|
11.5 B | $ 92.05 | -0.56 % | $ 135 B | USA |
 |
Conformis
CFMS
|
23.2 M | - | - | $ 16.4 M | USA |
 |
CryoLife, Inc.
CRY
|
168 M | - | -4.14 % | $ 702 M | USA |
 |
EDAP TMS S.A.
EDAP
|
26.6 M | $ 2.95 | 2.41 % | $ 110 M |  France |
 |
Cardiovascular Systems
CSII
|
173 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-12.7 M | - | -10.19 % | $ 1.99 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
28.7 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
43.7 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
1.99 M | - | - | $ 111 M |  Canada |
 |
Eargo
EAR
|
14.3 M | - | - | $ 10.2 M | USA |
 |
Dynatronics Corporation
DYNT
|
6.01 M | - | 14.99 % | $ 929 K | USA |
 |
Intersect ENT, Inc.
XENT
|
50.2 M | - | - | $ 955 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
247 M | $ 9.63 | -2.37 % | $ 691 M | Israel |
 |
InMode Ltd.
INMD
|
317 M | $ 14.39 | -0.86 % | $ 1.14 B | Israel |
 |
Second Sight Medical Products
EYES
|
500 K | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
2.8 B | $ 164.13 | -0.79 % | $ 12.3 B | USA |
 |
IRIDEX Corporation
IRIX
|
21.8 M | $ 0.95 | 3.57 % | $ 15.3 M | USA |
 |
IRadimed Corporation
IRMD
|
56.3 M | $ 96.6 | 0.38 % | $ 1.22 B | USA |
 |
Accuray Incorporated
ARAY
|
147 M | $ 1.05 | -1.35 % | $ 108 M | USA |
 |
Avinger
AVGR
|
2 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
19.1 M | $ 12.47 | -1.89 % | $ 337 M | USA |
 |
FONAR Corporation
FONR
|
42.4 M | $ 14.85 | 0.68 % | $ 97.3 M | USA |
 |
AxoGen
AXGN
|
142 M | $ 29.92 | -1.55 % | $ 1.32 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
198 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
1.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
733 M | $ 40.08 | -1.82 % | $ 1.24 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
149 M | $ 17.94 | 1.92 % | $ 414 M | USA |
 |
Globus Medical
GMED
|
719 M | $ 86.11 | -0.67 % | $ 11.7 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
953 M | $ 13.58 | 1.19 % | $ 1.05 B | USA |
 |
Aziyo Biologics
AZYO
|
11.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Alphatec Holdings
ATEC
|
424 M | $ 19.92 | -0.2 % | $ 2.85 B | USA |
 |
LivaNova PLC
LIVN
|
871 M | $ 62.59 | -0.25 % | $ 3.39 B |  Britain |
|
LENSAR
LNSR
|
14.1 M | $ 11.53 | 0.17 % | $ 133 M | USA |
 |
Aethlon Medical
AEMD
|
1.36 M | $ 3.23 | -5.11 % | $ 5.04 M | USA |
 |
Establishment Labs Holdings
ESTA
|
110 M | $ 72.0 | -0.7 % | $ 2.03 B |  Costa-rica |